Predictive Oncology Corp (POAI) - Multiplikator forward rega marang pendapatan
Predictive Oncology relies on AWS cloud computing and external clinics, which impacts profitability. The forward P/S valuation history demonstrates the dynamics of capitalization relative to future sales, where the 27.60 mark indicates the current balance of demand. Sustainability is confirmed by the optimization of AI algorithms. High barriers to entry are established by a unique biobank and strict FDA oversight.
predictive-oncology.com - rincian analitis lan metrik utama (POAI)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Predictive Oncology|POAI - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Predictive Oncology Inc.|POAI - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku POAI|POAI - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Predictive Oncology|Likuiditas cepet predictive-oncology.com
- data bathi bisnis lan rasio investasi:
POAI - Bathi pungkasan|Proyeksi bathi mangsa ngarep Predictive Oncology|POAI - Kapitalisasi marang bathi|Pangali Forward P/E Predictive Oncology Inc.|POAI - Rasio P/E diaturake wutah|Pangali EV/EBITDA POAI|POAI - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Predictive Oncology|POAI - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan predictive-oncology.com|POAI - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Predictive Oncology
- data dodolan lan asil:
Analisis umum perusahaan:POAI (Predictive Oncology Corp)
Investors must assess the risk of overpaying for future growth by analyzing the ratio of market capitalization to expected revenue via the forward P/S metric. The scalability of the Predictive Oncology (POAI) AI platform, characterized by zero marginal costs, enhances operating leverage and converts sales growth into a rapid increase in profit, rendering the company's current valuation fundamentally justified and resilient to market volatility.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Intuitive ISRG|Rega forward marang dodolan DHR|BDX: Multiplikator forward rega marang pendapatan|STE - Multiplikator Forward P/S|West Pharmaceutical Services (WST) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan baxter.com|MASI (Masimo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group SpA STVN|Rasio rega marang prakiraan pendapatan Teleflex Inc (TFX)|Merit Medical Corp - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (icumed.com)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake LeMaitre Vascular Inc LMAT|AtriCure Corp (ATRC) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan STAA (STAAR Surgical Co)|Rasio rega marang prakiraan pendapatan ChromaDex Corporation|ZIMV: Rega forward marang dodolan|Multiplikator Forward P/S ANGO|CERS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S TKNO (Alpha Teknova Inc)|MGRM: Kapitalisasi marang prakiraan pendapatan|Sharps Tech - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake InfuSystem Holdings INFU|UTMD: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan KORU Medical|Multiplikator forward rega marang pendapatan NYXH|MBOT (Microbot Medical, Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S PDEX|Rasio kapitalisasi marang dodolan sing dikarepake zentek.com|Elutia - Multiplikator forward rega marang pendapatan|Milestone Scientific Inc - Rasio rega marang prakiraan pendapatan|NEXGEL, Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Retractable Technologies|HBIO (Harvard Bioscience, Inc.) - Multiplikator forward rega marang pendapatan|femasys.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Meihua Medical Technologies|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Callan JMB Corp CJMB|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|NeuroMetrix Corporation - Kapitalisasi marang prakiraan pendapatan
